{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T14:40:06Z","timestamp":1751467206445,"version":"3.41.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2025,3,27]],"date-time":"2025-03-27T00:00:00Z","timestamp":1743033600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,3,27]],"date-time":"2025-03-27T00:00:00Z","timestamp":1743033600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2018YFA0902802"],"award-info":[{"award-number":["2018YFA0902802"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82071777","82271877"],"award-info":[{"award-number":["82071777","82271877"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1245\/s10434-025-17154-7","type":"journal-article","created":{"date-parts":[[2025,3,30]],"date-time":"2025-03-30T12:44:55Z","timestamp":1743338695000},"page":"6141-6150","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Improving Urothelial Carcinoma Outcomes: The Powerful Combination of Neoadjuvant and Adjuvant Chemotherapy in the Perioperative Period"],"prefix":"10.1245","volume":"32","author":[{"given":"Jincong","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuxuan","family":"Song","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rui","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hanlin","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yun","family":"Peng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jilin","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shicong","family":"Lai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yiqing","family":"Du","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caipeng","family":"Qin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tao","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,3,27]]},"reference":[{"issue":"4","key":"17154_CR1","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1016\/j.eururo.2016.09.035","volume":"71","author":"G Gakis","year":"2017","unstructured":"Gakis G, et al. Systematic review on the fate of the remnant urothelium after radical cystectomy. Eur Urol. 2017;71(4):545\u201357.","journal-title":"Eur Urol."},{"issue":"7","key":"17154_CR2","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1111\/j.1464-410X.2010.09675.x","volume":"107","author":"JD Raman","year":"2011","unstructured":"Raman JD, et al. Incidence and survival of patients with carcinoma of the ureter and renal pelvis in the USA, 1973\u20132005. BJU Int. 2011;107(7):1059\u201364.","journal-title":"BJU Int."},{"issue":"1","key":"17154_CR3","doi-asserted-by":"publisher","first-page":"11","DOI":"10.3322\/caac.21166","volume":"63","author":"R Siegel","year":"2013","unstructured":"Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013;63(1):11\u201330.","journal-title":"CA Cancer J Clin."},{"issue":"3","key":"17154_CR4","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229\u201363.","journal-title":"CA Cancer J Clin."},{"issue":"2","key":"17154_CR5","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.eururo.2004.04.011","volume":"46","author":"W Oosterlinck","year":"2004","unstructured":"Oosterlinck W, et al. EAU guidelines on diagnosis and treatment of upper urinary tract transitional cell carcinoma. Eur Urol. 2004;46(2):147\u201354.","journal-title":"Eur Urol."},{"issue":"5","key":"17154_CR6","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1016\/j.eururo.2015.06.044","volume":"68","author":"M Roupr\u00eat","year":"2015","unstructured":"Roupr\u00eat M, et al. European association of urology guidelines on upper urinary tract urothelial cell carcinoma: 2015 update. Eur Urol. 2015;68(5):868\u201379.","journal-title":"Eur Urol."},{"issue":"1","key":"17154_CR7","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.juro.2009.08.154","volume":"183","author":"WJ Wu","year":"2010","unstructured":"Wu WJ, et al. Should patients with primary upper urinary tract cancer receive prophylactic intravesical chemotherapy after nephroureterectomy? J Urol. 2010;183(1):56\u201361.","journal-title":"J Urol."},{"issue":"1","key":"17154_CR8","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1007\/s00345-012-0957-3","volume":"31","author":"E Xylinas","year":"2013","unstructured":"Xylinas E, et al. Intravesical recurrence after radical nephroureterectomy for upper tract urothelial carcinomas: predictors and impact on subsequent oncological outcomes from a national multicenter study. World J Urol. 2013;31(1):61\u20138.","journal-title":"World J Urol."},{"issue":"6","key":"17154_CR9","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1016\/j.eururo.2009.12.032","volume":"57","author":"WM Li","year":"2010","unstructured":"Li WM, et al. Oncologic outcomes following three different approaches to the distal ureter and bladder cuff in nephroureterectomy for primary upper urinary tract urothelial carcinoma. Eur Urol. 2010;57(6):963\u20139.","journal-title":"Eur Urol."},{"issue":"2","key":"17154_CR10","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1111\/j.1442-2042.2008.02201.x","volume":"16","author":"G Novara","year":"2009","unstructured":"Novara G, et al. Independent predictors of contralateral metachronous upper urinary tract transitional cell carcinoma after nephroureterectomy: multi-institutional dataset from three European centers. Int J Urol. 2009;16(2):187\u201391.","journal-title":"Int J Urol."},{"key":"17154_CR11","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/s12894-015-0039-0","volume":"15","author":"MA Moriarty","year":"2015","unstructured":"Moriarty MA, et al. Evaluating the safety of intraoperative instillation of intravesical chemotherapy at the time of nephroureterectomy. BMC Urol. 2015;15:45.","journal-title":"BMC Urol."},{"issue":"1","key":"17154_CR12","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1186\/s12894-022-01112-6","volume":"22","author":"JH Tae","year":"2022","unstructured":"Tae JH, et al. Neoadjuvant versus adjuvant chemotherapy in upper tract urothelial carcinoma: a nationwide cohort study. BMC Urol. 2022;22(1):175.","journal-title":"BMC Urol."},{"issue":"5","key":"17154_CR13","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1016\/j.eururo.2020.07.003","volume":"79","author":"JJ Leow","year":"2021","unstructured":"Leow JJ, et al. Neoadjuvant and adjuvant chemotherapy for upper tract urothelial carcinoma: a 2020 systematic review and meta-analysis, and future perspectives on systemic therapy. Eur Urol. 2021;79(5):635\u201354.","journal-title":"Eur Urol."},{"issue":"1","key":"17154_CR14","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.eururo.2023.03.013","volume":"4","author":"M Roupr\u00eat","year":"2023","unstructured":"Roupr\u00eat M, et al. European association of urology guidelines on upper urinary tract urothelial carcinoma: 2023 update. Eur Urol. 2023;4(1):49\u201364.","journal-title":"Eur Urol."},{"issue":"12","key":"17154_CR15","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1093\/jjco\/hyad118","volume":"53","author":"K Takahashi","year":"2023","unstructured":"Takahashi K, et al. Comparison of neoadjuvant and adjuvant chemotherapy for upper tract urothelial carcinoma in real-world practice: a multicenter retrospective study. Jpn J Clin Oncol. 2023;53(12):1208\u201314.","journal-title":"Jpn J Clin Oncol."},{"issue":"5","key":"17154_CR16","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1007\/s00345-020-03550-z","volume":"39","author":"A Martini","year":"2021","unstructured":"Martini A, et al. Neoadjuvant and adjuvant immunotherapy in renal cell carcinoma. World J Urol. 2021;39(5):1369\u201376.","journal-title":"World J Urol."},{"issue":"3","key":"17154_CR17","doi-asserted-by":"publisher","first-page":"e247","DOI":"10.1016\/j.cllc.2021.09.010","volume":"23","author":"JV Heymach","year":"2022","unstructured":"Heymach JV, et al. Design and rationale for a phase III, double-blind, placebo-controlled study of neoadjuvant durvalumab + chemotherapy followed by adjuvant durvalumab for the treatment of patients with resectable stages II and III non-small-cell lung cancer: the AEGEAN trial. Clin Lung Cancer. 2022;23(3):e247\u201351.","journal-title":"Clin Lung Cancer."},{"issue":"2","key":"17154_CR18","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/S1470-2045(23)00541-7","volume":"25","author":"K Shitara","year":"2024","unstructured":"Shitara K, et al. Neoadjuvant and adjuvant pembrolizumab plus chemotherapy in locally advanced gastric or gastro-oesophageal cancer (KEYNOTE-585): an interim analysis of the multicentre, double-blind, randomised phase 3 study. Lancet Oncol. 2024;25(2):212\u201324.","journal-title":"Lancet Oncol."},{"issue":"26","key":"17154_CR19","doi-asserted-by":"publisher","first-page":"2903","DOI":"10.1200\/JCO.20.02914","volume":"39","author":"YK Kang","year":"2021","unstructured":"Kang YK, et al. PRODIGY: a phase III study of neoadjuvant docetaxel, oxaliplatin, and S-1 plus surgery and adjuvant s-1 versus surgery and adjuvant S-1 for resectable advanced gastric cancer. J Clin Oncol. 2021;39(26):2903\u201313.","journal-title":"J Clin Oncol."},{"key":"17154_CR20","doi-asserted-by":"publisher","unstructured":"Paajanen J, et al. Recurrence patterns and management after pleurectomy decortication for pleural mesothelioma. Ann Surg. Epub 15 Jan 2025. https:\/\/doi.org\/10.1097\/SLA.0000000000006627","DOI":"10.1097\/SLA.0000000000006627"},{"issue":"10","key":"17154_CR21","doi-asserted-by":"publisher","first-page":"6622","DOI":"10.1097\/JS9.0000000000001301","volume":"110","author":"RX Zhang","year":"2024","unstructured":"Zhang RX, et al. Long-term outcomes of intraoperative chemotherapy with 5-FU for colorectal cancer patients receiving curative resection (IOCCRC): a randomized, multicenter, prospective, phase III trial. Int J Surg. 2024;110(10):6622\u201331.","journal-title":"Int J Surg."},{"key":"17154_CR22","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.canlet.2019.02.048","volume":"452","author":"WD Yu","year":"2019","unstructured":"Yu WD, et al. Mechanisms and therapeutic potentials of cancer immunotherapy in combination with radiotherapy and\/or chemotherapy. Cancer Lett. 2019;452:66\u201370.","journal-title":"Cancer Lett."},{"issue":"8","key":"17154_CR23","first-page":"CD010260","volume":"8","author":"F Kokka","year":"2022","unstructured":"Kokka F, et al. Hysterectomy with radiotherapy or chemotherapy or both for women with locally advanced cervical cancer. Cochrane Database Syst Rev. 2022;8(8):CD010260.","journal-title":"Cochrane Database Syst Rev."},{"issue":"1","key":"17154_CR24","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1615\/CritRevBiomedEng.v38.i1.80","volume":"38","author":"W Rao","year":"2010","unstructured":"Rao W, Deng ZS, Liu J. A review of hyperthermia combined with radiotherapy\/chemotherapy on malignant tumors. Crit Rev Biomed Eng. 2010;38(1):101\u201316.","journal-title":"Crit Rev Biomed Eng."},{"issue":"4","key":"17154_CR25","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1016\/j.eururo.2010.06.029","volume":"58","author":"MG Kaag","year":"2010","unstructured":"Kaag MG, et al. Changes in renal function following nephroureterectomy may affect the use of perioperative chemotherapy. Eur Urol. 2010;58(4):581\u20137.","journal-title":"Eur Urol."},{"issue":"4","key":"17154_CR26","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1111\/j.1464-410X.2012.11649.x","volume":"112","author":"E Xylinas","year":"2013","unstructured":"Xylinas E, et al. Impact of renal function on eligibility for chemotherapy and survival in patients who have undergone radical nephro-ureterectomy. BJU Int. 2013;112(4):453\u201361.","journal-title":"BJU Int."},{"issue":"5","key":"17154_CR27","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1111\/bju.12597","volume":"114","author":"M Kaag","year":"2014","unstructured":"Kaag M, et al. Preoperative predictors of renal function decline after radical nephroureterectomy for upper tract urothelial carcinoma. BJU Int. 2014;114(5):674\u20139.","journal-title":"BJU Int."},{"issue":"1","key":"17154_CR28","doi-asserted-by":"publisher","first-page":"31.e17","DOI":"10.1016\/j.urolonc.2012.11.014","volume":"32","author":"FA Yafi","year":"2014","unstructured":"Yafi FA, et al. Adjuvant chemotherapy for upper-tract urothelial carcinoma treated with nephroureterectomy: assessment of adequate renal function and influence on outcome. Urol Oncol. 2014;32(1):31.e17-24.","journal-title":"Urol Oncol."},{"issue":"11","key":"17154_CR29","doi-asserted-by":"publisher","first-page":"3205","DOI":"10.1007\/s00345-023-04330-1","volume":"41","author":"U Pinar","year":"2023","unstructured":"Pinar U, et al. The role of perioperative chemotherapy for upper tract urothelial carcinoma patients treated with radical nephroureterectomy. World J Urol. 2023;41(11):3205\u201330.","journal-title":"World J Urol."},{"issue":"4","key":"17154_CR30","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1007\/s00432-024-05684-8","volume":"150","author":"J Li","year":"2024","unstructured":"Li J, et al. The role of histological subtype and chemotherapy on prognosis of ureteral cancer. J Cancer Res Clin Oncol. 2024;150(4):192.","journal-title":"J Cancer Res Clin Oncol."},{"issue":"1","key":"17154_CR31","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.eururo.2017.07.036","volume":"73","author":"M Roupr\u00eat","year":"2018","unstructured":"Roupr\u00eat M, et al. European association of urology guidelines on upper urinary tract urothelial carcinoma: 2017 update. Eur Urol. 2018;73(1):111\u201322.","journal-title":"Eur Urol."},{"issue":"6","key":"17154_CR32","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1016\/j.ccell.2021.05.008","volume":"39","author":"Y Fujii","year":"2021","unstructured":"Fujii Y, et al. Molecular classification and diagnostics of upper urinary tract urothelial carcinoma. Cancer Cell. 2021;39(6):793-809.e8.","journal-title":"Cancer Cell."},{"issue":"34","key":"17154_CR33","doi-asserted-by":"publisher","first-page":"3353","DOI":"10.1200\/JCO.18.01148","volume":"36","author":"A Necchi","year":"2018","unstructured":"Necchi A, et al. Pembrolizumab as neoadjuvant therapy before radical cystectomy in patients with muscle-invasive urothelial bladder carcinoma (PURE-01): an open-label, single-arm, phase II study. J Clin Oncol. 2018;36(34):3353\u201360.","journal-title":"J Clin Oncol."},{"issue":"2","key":"17154_CR34","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/j.eururo.2022.04.013","volume":"82","author":"B Szabados","year":"2022","unstructured":"Szabados B, et al. Final results of neoadjuvant atezolizumab in cisplatin-ineligible patients with muscle-invasive urothelial cancer of the bladder. Eur Urol. 2022;82(2):212\u201322.","journal-title":"Eur Urol."},{"issue":"2","key":"17154_CR35","doi-asserted-by":"publisher","first-page":"168","DOI":"10.4111\/icu.20210407","volume":"63","author":"HH Sung","year":"2022","unstructured":"Sung HH, et al. Neoadjuvant chemotherapy with gemcitabine and cisplatin followed by selective bladder preservation chemoradiotherapy in muscle-invasive urothelial carcinoma of bladder. Investig Clin Urol. 2022;63(2):168\u201374.","journal-title":"Investig Clin Urol."},{"issue":"2","key":"17154_CR36","doi-asserted-by":"publisher","first-page":"636","DOI":"10.4143\/crt.2022.343","volume":"55","author":"H Kim","year":"2023","unstructured":"Kim H, et al. Neoadjuvant nivolumab plus gemcitabine\/cisplatin chemotherapy in muscle-invasive urothelial carcinoma of the bladder. Cancer Res Treat. 2023;55(2):636\u201342.","journal-title":"Cancer Res Treat."},{"issue":"6","key":"17154_CR37","doi-asserted-by":"publisher","first-page":"274.e15","DOI":"10.1016\/j.urolonc.2022.02.002","volume":"40","author":"M Bharadwaj","year":"2022","unstructured":"Bharadwaj M, et al. Adjuvant chemotherapy versus observation following radical cystectomy for locally advanced urothelial carcinoma of the bladder. Urol Oncol. 2022;40(6):274.e15-274.e23.","journal-title":"Urol Oncol."},{"issue":"11","key":"17154_CR38","doi-asserted-by":"publisher","first-page":"3641","DOI":"10.31557\/APJCP.2022.23.11.3641","volume":"23","author":"A Sawasdee","year":"2022","unstructured":"Sawasdee A, Tanthanuch M, Bejrananda T. Neoadjuvant versus Adjuvant Chemotherapy in Patients with Resectable Muscle-Invasive Bladder Cancer. Asian Pac J Cancer Prev. 2022;23(11):3641\u20137.","journal-title":"Asian Pac J Cancer Prev"},{"issue":"3","key":"17154_CR39","doi-asserted-by":"publisher","first-page":"105.e19","DOI":"10.1016\/j.urolonc.2021.07.029","volume":"40","author":"K Shigeta","year":"2022","unstructured":"Shigeta K, et al. Does neoadjuvant chemotherapy have therapeutic benefit for node-positive upper tract urothelial carcinoma? Results of a multi-center cohort study. Urol Oncol. 2022;40(3):105.e19-105.e26.","journal-title":"Urol Oncol."},{"issue":"5","key":"17154_CR40","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1007\/s12032-014-0949-9","volume":"31","author":"T Koie","year":"2014","unstructured":"Koie T, et al. Neoadjuvant gemcitabine and carboplatin followed by immediate cystectomy may be associated with a survival benefit in patients with clinical T2 bladder cancer. Med Oncol. 2014;31(5):949.","journal-title":"Med Oncol."},{"issue":"1","key":"17154_CR41","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/iju.12230","volume":"21","author":"C Ohyama","year":"2014","unstructured":"Ohyama C, et al. Neoadjuvant chemotherapy with gemcitabine plus carboplatin followed by immediate radical cystectomy for muscle-invasive bladder cancer. Int J Urol. 2014;21(1):3\u20134.","journal-title":"Int J Urol."},{"issue":"4","key":"17154_CR42","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1016\/j.urolonc.2010.07.016","volume":"31","author":"F Audenet","year":"2013","unstructured":"Audenet F, et al. The role of chemotherapy in the treatment of urothelial cell carcinoma of the upper urinary tract (UUT-UCC). Urol Oncol. 2013;31(4):407\u201313.","journal-title":"Urol Oncol."},{"issue":"2","key":"17154_CR43","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1007\/s10147-016-1071-0","volume":"22","author":"K Fukushi","year":"2017","unstructured":"Fukushi K, et al. Quality-of-life evaluation during platinum-based neoadjuvant chemotherapies for urothelial carcinoma. Int J Clin Oncol. 2017;22(2):366\u201372.","journal-title":"Int J Clin Oncol."},{"issue":"1","key":"17154_CR44","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.eururo.2006.12.029","volume":"52","author":"L Dogliotti","year":"2007","unstructured":"Dogliotti L, et al. Gemcitabine plus cisplatin versus gemcitabine plus carboplatin as first-line chemotherapy in advanced transitional cell carcinoma of the urothelium: results of a randomized phase 2 trial. Eur Urol. 2007;52(1):134\u201341.","journal-title":"Eur Urol."}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-025-17154-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-025-17154-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-025-17154-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T13:59:18Z","timestamp":1751464758000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1245\/s10434-025-17154-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,27]]},"references-count":44,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["17154"],"URL":"https:\/\/doi.org\/10.1245\/s10434-025-17154-7","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"type":"print","value":"1068-9265"},{"type":"electronic","value":"1534-4681"}],"subject":[],"published":{"date-parts":[[2025,3,27]]},"assertion":[{"value":"11 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Jincong Li, Yuxuan Song, Rui Chen, Hanlin Gao, Yang Liu, Yun Peng, Jilin Wu, Shicong Lai, Yiqing Du, Caipeng Qin, and Tao Xu declare they have no conflicts of interest that may be relevant to the contents of this article.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosure"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}]}}